Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Sonki who wrote (1311)	4/20/1998 9:55:00 PM
From: Nick	Read Replies (1) \| Respond to of 9523

Just a little something from Motley Fool last week: We'll start with Pfizer (NYSE: PFE), whose main news is still Viagra-centric. The male impotence drug stormed the market last week. Sales have already been described as "enormous" and "over $75 million on the first day," and our company literally hasn't even started advertising the product yet. Viagra even has its own website now, at www.viagra.com. Pfizer's stock leapt to a new high yet again today, on Monday, due to more publicity for Viagra. Viagra is one of fastest-selling drugs in history since its launch. Pfizer may also be benefiting from the record pollen levels in Oregon, Arizona, Florida, Southern California, Colorado, New York City, and North Carolina. Oh, and here in Texas, too. (Achooooo!) Our company certainly isn't holding back on advertisements of its allergy product, Zyrtec. It looks to me like Pfizer can clean up on this one. Drop by the company's resource center on allergies for more info at www.allergy-info.com. Oh yeah, Pfizer also released a solid earnings report, with first quarter revenues up 11% from last year and net earnings up 15%. Our company held its cost of sales flat on that growth, which made for an improvement in gross margins of nearly two percentage points. Pfizer's gross margins for the quarter rang in at a whopping 83.7%. For a look at its Q1 earnings report on the Web, click here: PFE Reports First Quarter. If I sound enthusiastic, it's because Pfizer rose another $4 1/2 on Friday to $105 3/16 per share. The stock has now risen 27.8% for us since early February (and much more following the update of today's numbers this afternoon). Pfizer stock has doubled over the past year, and is trading at Himalayan multiples. Its prospects, however, may be even higher. Of course, our eyes are trained on the next ten years, not months, with a focus on the strength of its balance sheet and product line.